These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31413526)

  • 1. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.
    Colombo MG; Musabaev EI; Ismailov UY; Zaytsev IA; Nersesov AV; Anastasiy IA; Karpov IA; Golubovska OA; Kaliaskarova KS; Ac R; Hadigal S
    World J Gastroenterol; 2019 Aug; 25(29):3897-3919. PubMed ID: 31413526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation.
    Charlton MR; Gane EJ; Shukla A; Dashtseren B; Duger D; Muljono DH; Payawal DA; Jargalsaikhan G; Purnomo HD; Cua IH; Hasan I; Sollano J; Win KM; Lesmana LA; Salih M; Thi Thu Thuy P; Shankar R; Saraswat VA
    Transplantation; 2019 Apr; 103(4):733-746. PubMed ID: 30335692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study.
    Jančorienė L; Rozentāle B; Tolmane I; Jēruma A; Salupere R; Buivydienė A; Valantinas J; Kupčinskas L; Šumskienė J; Čiupkevičienė E; Ambrozaitis A; Golubovska O; Moroz L; Flisiak R; Bondar B
    Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763696
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society?
    Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
    Liver Int; 2017 May; 37(5):662-668. PubMed ID: 27804195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C in Asia: when East meets West.
    Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.
    Boyd SD; Harrington P; Komatsu TE; Naeger LK; Chan-Tack K; Murray J; Birnkrant D; Struble K
    J Viral Hepat; 2018 Aug; 25(8):969-975. PubMed ID: 29577495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urgency to treat patients with chronic hepatitis C in Asia.
    Kao JH; Ahn SH; Chien RN; Cho M; Chuang WL; Jeong SH; Liu CH; Paik SW
    J Gastroenterol Hepatol; 2017 May; 32(5):966-974. PubMed ID: 28005275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6.
    Lawitz E; Gane E; Feld JJ; Buti M; Foster GR; Rabinovitz M; Burnevich E; Katchman H; Tomasiewicz K; Lahser F; Jackson B; Shaughnessy M; Klopfer S; Yeh WW; Robertson MN; Hanna GJ; Barr E; Platt HL;
    J Viral Hepat; 2019 Sep; 26(9):1127-1138. PubMed ID: 31108015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection.
    Mettikanont P; Bunchorntavakul C; Reddy KR
    Aliment Pharmacol Ther; 2019 Mar; 49(5):492-505. PubMed ID: 30687952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.
    Backx M; Lewszuk A; White JR; Cole J; Sreedharan A; van Sanden S; Diels J; Lawson A; Neal KR; Wiselka MJ; Ito T; Irving WL
    J Viral Hepat; 2014 Mar; 21(3):208-15. PubMed ID: 24438682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    Hézode C
    J Viral Hepat; 2017 Feb; 24(2):92-101. PubMed ID: 27862695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6.
    Asselah T; Hassanein T; Waked I; Mansouri A; Dusheiko G; Gane E
    J Hepatol; 2018 Apr; 68(4):814-826. PubMed ID: 29229584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hepatitis C: a systematic review.
    Kohli A; Shaffer A; Sherman A; Kottilil S
    JAMA; 2014 Aug; 312(6):631-40. PubMed ID: 25117132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
    Sirinawasatien A; Techasirioangkun T
    PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection.
    Lawitz E; Poordad F; Anderson LJ; Vesay M; Kelly MM; Liu H; Gao W; Fernsler D; Asante-Appiah E; Robertson MN; Hanna GJ; Barr E; Butterton J; Kowdley KV; Hassanein T; Sahota A; Gordon SC; Yeh WW
    J Viral Hepat; 2019 Jun; 26(6):675-684. PubMed ID: 30739366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.